Life
Briefing: Pharma Delays Launches in Europe Amid U.S. Pressure
Strategic angle: Drugmakers are postponing the release of new medicines in Europe due to shifting pricing policies and pressures from the U.S.
editorial-staff
1 min read
Updated 11 days ago
Pharmaceutical companies are currently facing significant challenges in launching new drugs in the European market. This situation is primarily driven by evolving pricing policies in the United States.
The delays in drug launches are raising concerns about the potential impact on healthcare systems in Europe, as timely access to new treatments may be hindered.
Key players in this scenario include Lilly and Biogen, both of which are reportedly adjusting their strategies in response to these pressures.